Solar plexus electrical stimulation system used for treating type 2 diabetes mellitus

Abstract

The invention discloses a solar plexus electrical stimulation system used for treating type 2 diabetes mellitus. The system comprises an in-vitro program control instrument, an individual controller, an in-vivo stimulator implanted under the skin of the lateral abdomen of a patient to emit an electric pulse, and an electrode implanted into the solar plexus of the patient, wherein the in-vitro program control instrument is connected with the individual controller through a data cable; the individual controller is connected with the in-vivo stimulator in a radio-frequency communication manner; the in-vivo stimulator is connected with the electrode through a conducting wire; the in-vitro program control instrument is a computer equipped with operation software of the solar plexus electrical stimulation system; the individual controller integrates a functional module E type amplifier; the in-vivo stimulator comprises four functional units, namely a radio-frequency receiver, a micro processor, a double-channel pulse generator and a power supply system; the electrode is a bipolar electrode. The invention discovers that the solar plexus block can be used for the treatment of the type 2 diabetes mellitus; the solar plexus electrical stimulation system is simple, convenient and flexible in operation, can be used for effectively treating diabetes with few complications.

Description

technical field [0001] The invention belongs to the field of medical devices, in particular to a celiac plexus electrical stimulation system for treating type 2 diabetes. Background technique [0002] Type 2 diabetes (Diabetes mellitus type 2), formerly known as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes (adult-onset diabetes), is a metabolic disease characterized by hyperglycemia, Mainly caused by insulin resistance and relative lack of insulin. Type 1 diabetes is different in that the body of type 1 diabetics has completely lost the ability to produce insulin because the islet cells in the pancreas have been damaged. Type 2 diabetes accounts for about 90% of diabetic patients, and the remaining 10% is mainly type 1 diabetes and gestational diabetes. [0003] The traditional treatment of diabetes is mainly internal medicine, but drug therapy and insulin use are difficult to cure, patients can not get rid of the pain of taking medicine for life...

AI Technical Summary

Problems solved by technology

[0003] The traditional treatment of diabetes is mainly internal medicine, but drug therapy and insulin use are difficult to cure, patients cannot get rid of the pain of taking medicine for life, and the quality of life is seriously affected

In addition, current studies have shown that surgical operations can also treat NIDDM, such as gastric volume reduction surgery, gastric bypass surgery, and ileal transposition, but the surgery itself is traumatic and has many complications

Cutting-edge technologies such as islet cell transplantation and mesenchymal stem cell transplantation are also expected to bring hope for the cure of diabetes, but they still face problems such as insufficient source of donor cells, high technical difficulty, and high cost, which affect their widespread promotion

Images